Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, China.
Medicine (Baltimore). 2023 Oct 13;102(41):e35552. doi: 10.1097/MD.0000000000035552.
Kaposi sarcoma (KS) is the most common cancer in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (AIDS). In 1994, Chang and Moore discovered Kaposi sarcoma associated herpesvirus for the first time in KS lesions in AIDS patients. KS is a low-grade mesenchymal neoplasm of blood and lymphatic vessels that primarily affects the skin, although the disease may become disseminated to the lymphatic system, lungs, airways, or abdominal viscera. In this research, clinical characteristics and treatment of patients of Kaposi sarcoma were retrospectively analyzed in Hotan District, Xinjiang China. We look into the clinical traits, prognosis, and therapy of Kaposi sarcoma. From May 2017 to August 2022, 32 patients were treated in the People's Hospital of Hotan District, Xinjiang Uygur Autonomous Region, China. Twenty-two of these were classic Kaposi sarcomas (cKS), and 10 of these were Kaposi sarcomas linked to AIDS (AIDS-KS). The majority of KS patients were Uyghur. In terms of age at onset, AIDS-KS patients were younger than cKS patients. cKS and AIDS-KS are most frequently manifested in the feet and lower limbs. Ten patients with AIDS-KS have treated with combination antiretroviral therapy (combination antiretroviral therapy) combination chemotherapy, 5 of 10 patients had a complete response, 2 patients achieved partial response, the overall effective rate was 70%, and CD4 + T cells were greater than before. For cKS and AIDS-KS, the median overall survival was 56 and 50.8 months, respectively (P > .05). As a result, antiviral combination chemotherapy can also improve the prognosis of AIDS-KS patients.
卡波西肉瘤（KS）是人类免疫缺陷病毒/获得性免疫缺陷综合征（AIDS）患者中最常见的癌症。1994 年，Chang 和 Moore 首次在 AIDS 患者的 KS 病变中发现卡波西肉瘤相关疱疹病毒。KS 是一种低级别间充质肿瘤，主要影响血管和淋巴管，尽管该疾病可能扩散到淋巴系统、肺部、气道或腹部内脏。在这项研究中，回顾性分析了中国新疆和田地区 KS 患者的临床特征和治疗方法。我们研究了卡波西肉瘤的临床特征、预后和治疗方法。2017 年 5 月至 2022 年 8 月，新疆维吾尔自治区和田地区人民医院共治疗 32 例患者。其中 22 例为经典卡波西肉瘤（cKS），10 例为艾滋病相关卡波西肉瘤（AIDS-KS）。KS 患者多数为维吾尔族。在发病年龄方面，AIDS-KS 患者比 cKS 患者年轻。cKS 和 AIDS-KS 最常发生在足部和下肢。10 例 AIDS-KS 患者接受了联合抗逆转录病毒治疗（combination antiretroviral therapy，cART）联合化疗，10 例患者中 5 例完全缓解，2 例部分缓解，总有效率为 70%，且 CD4+T 细胞较前增加。cKS 和 AIDS-KS 的中位总生存期分别为 56 和 50.8 个月（P >.05）。因此，抗病毒联合化疗也能改善 AIDS-KS 患者的预后。
